Evidence map›Paper›PMID 41588315›Full record

ArticleMolecular pharmaceutics2026

Synthesis and Evaluation of D8W, an Octadentate Desferrioxamine Analogue with Enhanced Water Solubility Designed for

James L Wood, Saikat Ghosh, Callum A Rosser, Samuel V Feeney, Christopher J M Brown, Nicholas L Fletcher, Michael P Wheatcroft, Kristofer J Thurecht, Rachel Codd

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

James L WoodAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia.ORCID 0000-0001-8755-779X
Saikat GhoshAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia.
Callum A RosserSchool of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID 0009-0000-4166-1997
Samuel V FeeneySchool of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
Christopher J M BrownSchool of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID 0000-0003-2272-3720
Nicholas L FletcherAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia.ORCID 0000-0002-2993-833X
Michael P WheatcroftTelix Pharmaceuticals Limited, North Melbourne, Victoria 3051, Australia.
Kristofer J ThurechtAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia.ORCID 0000-0002-4100-3131
Rachel CoddSchool of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID 0000-0002-2703-883X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-based zirconium-89 (

Indexed as

DeferoxaminePositron-Emission TomographyRadioisotopesRadiopharmaceuticalsZirconiumAnimalsAntibodies, MonoclonalChelating AgentsHumansMiceSolubilityTissue DistributionWaterAntibodies, MonoclonalChelating AgentsDeferoxamineRadioisotopesRadiopharmaceuticalsWaterZirconiumZirconium-89cancerchelator chemistryimagingimmunoPETrodent modelszirconium-89

Identifiers

PMID41588315
PMCPMC12958288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.